Ichnos Glenmark Innovation (IGI), a global, fully integrated clinical-stage biotechnology company focused on developing multi specifics in oncology,  announced its global commercialization strategy with Abbvie for its lead investigational asset, ISB 2001 developed using IGI’s proprietary BEAT protein platform, for oncology and autoimmune diseases.

Under the terms of agreement, IGI partners with AbbVie and grants exclusive rights to globally develop, manufacture, and commercialize ISB 2001 across North America, Europe, Japan, and Greater China while Glenmark Pharmaceuticals will develop, manufacture and lead commercialization of ISB 2001 across Emerging Markets including the rest of Asia, Latin America, the Russia/CIS region, the Middle East, Africa, Australia, New Zealand and South Korea.

“Our collaboration with AbbVie and Glenmark reflects IGI’s mission to accelerate access to transformative multi specifics for patients worldwide,” said Cyril Konto, President, Executive Director & CEO, IGI.

“AbbVie’s reach in major markets combined with Glenmark’s commercial strength in Emerging Markets, creates complementary access pathways for ISB 2001, a trispecific T-cell engager with promising potential in Multiple Myeloma,” added Konto.

“At Glenmark, we are committed to expanding access to innovative cancer treatments across Emerging Markets where unmet need and growth potential intersect,” said Christoph Stoller, President – Europe and Emerging Markets, Glenmark Pharmaceuticals.

“The addition of ISB 2001 is a natural evolution of our oncology strategy. With our deep commercial footprint, strong regulatory capabilities, and experience in launching breakthrough assets like BRUKINSA and TEVIMBRA in India, and rights to commercialize QiNHAYO (envafolimab), a PD-L1 checkpoint inhibitor, in Emerging Markets, we are well positioned to deliver impactful treatment option for patients with difficult-to-treat cancers through ISB 2001,” added Stoller.

This strategic collaboration marks a defining milestone in IGI’s scientific journey, accelerating ISB 2001’s path to patients and sharpening the focus on advancing the next generation of BEAT-enabled assets in oncology.